We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CSL Limited | ASX:CSL | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80 | -0.65% | 276.37 | 276.00 | 276.90 | 277.41 | 275.14 | 276.16 | 1,560,327 | 07:50:00 |
From Dec 2019 to Dec 2024
23:08 GMT [Dow Jones] CSL (CSL.AU), Australia's largest pharmaceuticals group, is nursing a cold from the flu-vaccines business it bought from Novartis in a deal that completed in August. CSL signaled a US$130 million underlying net loss on the business in FY16, contributing to Goldman Sachs lowering its FY16-FY18 EPS forecasts by 1%-6%. Still, the broker retains a buy call on the stock. "We believe investors will likely regards FY17 metrics as a better reflection of the company's underlying earnings (whereas FY16 incorporates flu losses ahead of the restructuring program)," analyst Ian Abbott says. CSL last traded at A$88.99. (david.winning@wsj.com; @dwinningWSJ)
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
October 15, 2015 19:22 ET (23:22 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year CSL Chart |
1 Month CSL Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
